First Trust Advisors LP Halozyme Therapeutics, Inc. Transaction History

First Trust Advisors LP

$101 Billion
Q3 2024

A detailed history of First Trust Advisors LP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, First Trust Advisors LP holds 876,863 shares of HALO stock, worth $37.3 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

876,863

Previous 1,026,166 14.55%

Holding current value

$37.3 Million

Previous $53.7 Million 6.64%

% of portfolio

0.05%

Previous 0.06%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$51.3 - $64.42 $7.66 Million - $9.62 Million	-149,303 Reduced 14.55%	876,863 $50.2 Million
Q2 2024 Aug 13, 2024	SELL	$37.81 - $52.4 $6.36 Million - $8.82 Million	-168,298 Reduced 14.09%	1,026,166 $53.7 Million
Q1 2024 May 13, 2024	BUY	$33.68 - $41.95 $37.1 Million - $46.3 Million	1,102,623 Added 1200.58%	1,194,464 $48.6 Million
Q4 2023 Feb 13, 2024	BUY	$33.32 - $42.1 $2.81 Million - $3.55 Million	84,288 Added 1115.95%	91,841 $3.39 Million
Q3 2023 Nov 13, 2023	BUY	$36.46 - $44.03 $70,768 - $85,462	1,941 Added 34.59%	7,553 $288,000
Q2 2023 Aug 14, 2023	SELL	$30.28 - $38.74 $3.02 Million - $3.86 Million	-99,668 Reduced 94.67%	5,612 $202,000
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $1.68 Million - $2.85 Million	51,110 Added 94.35%	105,280 $4.02 Million
Q4 2022 Feb 09, 2023	SELL	$40.06 - $59.44 $2.28 Million - $3.38 Million	-56,923 Reduced 51.24%	54,170 $3.08 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $1.18 Million - $1.59 Million	30,639 Added 38.08%	111,093 $4.39 Million
Q2 2022 Aug 12, 2022	BUY	$37.35 - $48.3 $1.08 Million - $1.39 Million	28,865 Added 55.95%	80,454 $3.54 Million
Q1 2022 May 13, 2022	SELL	$31.97 - $41.06 $164,261 - $210,966	-5,138 Reduced 9.06%	51,589 $2.06 Million
Q4 2021 Feb 08, 2022	SELL	$31.82 - $40.75 $2.08 Million - $2.67 Million	-65,434 Reduced 53.56%	56,727 $2.28 Million
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $1.46 Million - $1.76 Million	37,835 Added 44.87%	122,161 $4.97 Million
Q2 2021 Aug 16, 2021	SELL	$38.84 - $51.31 $2.13 Million - $2.81 Million	-54,754 Reduced 39.37%	84,326 $3.83 Million
Q1 2021 May 14, 2021	BUY	$39.51 - $51.45 $2.22 Million - $2.89 Million	56,213 Added 67.84%	139,080 $5.8 Million
Q4 2020 Feb 02, 2021	BUY	$25.81 - $43.62 $598,508 - $1.01 Million	23,189 Added 38.86%	82,867 $3.54 Million
Q3 2020 Nov 05, 2020	SELL	$25.74 - $29.63 $1.04 Million - $1.2 Million	-40,388 Reduced 40.36%	59,678 $1.57 Million
Q2 2020 Jul 22, 2020	BUY	$16.25 - $26.81 $1.4 Million - $2.32 Million	86,443 Added 634.54%	100,066 $2.68 Million
Q1 2020 May 06, 2020	BUY	$13.9 - $21.83 $189,359 - $297,390	13,623 New	13,623 $245,000
Q4 2019 Feb 03, 2020	SELL	$14.93 - $19.53 $644,080 - $842,524	-43,140 Closed	0 $0
Q3 2019 Nov 04, 2019	BUY	$15.2 - $17.69 $655,728 - $763,146	43,140 New	43,140 $669,000
Q2 2019 Jul 30, 2019	SELL	$14.75 - $17.26 $1.44 Million - $1.69 Million	-97,659 Closed	0 $0
Q1 2019 May 09, 2019	BUY	$13.94 - $17.58 $213,560 - $269,325	15,320 Added 18.61%	97,659 $1.57 Million
Q4 2018 Feb 07, 2019	BUY	$13.33 - $18.66 $617,192 - $863,976	46,301 Added 128.48%	82,339 $1.21 Million
Q3 2018 Oct 25, 2018	SELL	$16.68 - $18.41 $2.05 Million - $2.26 Million	-122,943 Reduced 77.33%	36,038 $655,000
Q2 2018 Aug 02, 2018	BUY	$16.87 - $20.3 $1.25 Million - $1.51 Million	74,161 Added 87.43%	158,981 $2.68 Million
Q1 2018 Apr 23, 2018	BUY	$17.06 - $21.2 $112,067 - $139,262	6,569 Added 8.39%	84,820 $1.66 Million
Q4 2017 Feb 08, 2018	BUY	$16.75 - $20.8 $681,892 - $846,768	40,710 Added 108.44%	78,251 $1.59 Million
Q3 2017 Oct 24, 2017	BUY	$11.76 - $17.4 $441,482 - $653,213	37,541	37,541 $652,000

Others Institutions Holding HALO

# of Institutions

542

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $5.93B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.

Account

First Trust Advisors LP Halozyme Therapeutics, Inc. Transaction History